The invention relates to an applicator for inserting an implant under the skin of a patient. The applicator (1) comprises a housing (10) containing a cannula (30) that is fixed to a cannula holder (22) and is slidably received within said housing. The cannula comprises an aperture (32) at its distal end and a lateral opening (34). The implant (50) is accommodated within the cannula and/or the cannula holder. A securing mechanism (40) retains the implant inside the cannula. This mechanism comprises an arm (42) configurable between a first position, which prevents the implant from exiting through the cannula's aperture, and a second position that enables the implant's placement under the skin through the aperture. Said lateral opening is situated between the aperture and the distal end of the implant when the implant is secured inside the cannula and/or the cannula holder.
Embodiments of the invention relate to an applicator for inserting an implant under the skin of a patient. The applicator comprises a housing containing a cannula that is fixed to a cannula holder and is slidably received within said housing. The cannula comprises an aperture at its distal end and a lateral opening. The implant is accommodated within the cannula and/or the cannula holder. A securing mechanism retains the implant inside the cannula. This mechanism comprises an arm configurable between a first position, which prevents the implant from exiting through the cannula's aperture, and a second position that enables the implant's placement under the skin through the aperture. Said lateral opening is situated between the aperture and the distal end of the implant. In the first arm position, the arm partially enters the lateral opening, thereby obstructing the implant from exiting through the aperture.
The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea, comprising administering drospirenone in a biphasic regimen. The present invention furthermore relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to a pharmaceutical composition and a kit comprising drospirenone administered in such a biphasic regimen.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; medicines for veterinary use;
sanitary articles and preparations; vitamins and vitamin
preparations; nutritional supplements; mineral dietary
supplements; dietetic substances for medical use; dietary
supplements for medical use; dietary supplements;
nutritional supplements; chemical contraceptives.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; medicines for veterinary use;
sanitary articles and preparations; vitamins and vitamin
preparations; nutritional supplements; mineral dietary
supplements; dietetic substances for medical use; dietary
supplements for medical use; dietary supplements;
nutritional supplements; chemical contraceptives.
9.
NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION
The invention relates to a new modified release oral pharmaceutical form comprising 17α-cyanomethyl-17-ß-hydroxyestra-4,9-dien-3-one (dienogest) and 17α-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea, comprising administering drospirenone in a biphasic regimen. The present invention furthermore relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to a pharmaceutical composition and a kit comprising drospirenone administered in such a biphasic regimen.
The present invention relates to a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 μg/day to about 100 μg/day. The invention further relates to a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea comprising continuously administering about 60 μg/day to about 160 μg/day of levonorgestrel. Delivery devices, such as, intravaginal rings for putting the methods in practice are also envisaged.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
12.
METHOD AND DEVICE FOR PROVIDING EFFECTIVE CONTRACEPTION
The present invention relates to levonorgestrel for use in a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 µg/day to about 100 µg/day. The invention further relates to levonorgestrel for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea comprising continuously administering about 60 µg/day to about 160 µg/day of levonorgestrel. Delivery devices, preferably, intravaginal rings for putting the methods in practice are also envisaged.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 μg/day to about 100 μg/day. The invention further relates to a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea comprising continuously administering about 60 μg/day to about 160 μg/day of levonorgestrel. Delivery devices, such as, intravaginal rings for putting the methods in practice are also envisaged.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, veterinary and sanitary preparations; Vitamins, Nutritional supplements, Mineral dietary supplements, Nutritional supplements, Dietetic and nutritional supplements; Chemical contraceptives.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, veterinary and sanitary preparations; Vitamins, Nutritional supplements, Mineral dietary supplements, Nutritional supplements, Dietetic and nutritional supplements; Chemical contraceptives.
25.
IMPROVED METHOD FOR THE SCREENING, DIAGNOSIS OR MONITORING OF ENDOMETRIOSIS, KIT AND USES THEREOF
The present invention relates to an improved non-invasive method for the screening, diagnosis or monitoring of endometriosis in a subject, comprising the determination of the protein levels of a group of biomarkers comprising or consisting of brain-derived neurotrophic factor (BDNF) and/or cancer antigen 125 (CA125) in a biological sample, optionally in combination with variables related to the subject's history and/or clinical characteristics. It further relates to a kit for determining the protein levels of BDNF and/or CA125 and the use of the kit in the methods of the invention.
The invention relates to a new modified release oral pharmaceutical form comprising 17α-cyanomethyl-17-β-hydrox-yestra-4,9-dien-3-one (dienogest) and 17aα-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea, comprising administering drospirenone in a biphasic regimen. The present invention furthermore relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to a pharmaceutical composition and a kit comprising drospirenone administered in such a biphasic regimen.
Ligilactobacillus salivariusLigilactobacillus salivarius, compositions comprising it and uses thereof in the prevention and/or treatment of infertility and infection diseases as well as non-therapeutic applications.
The present invention concerns a treatment of Long COVID-19 by using specialized pro-resolving lipid mediators (SPM) or their active precursors, optionally in combination with a non-steroidal anti- inflammatory drug.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention pertains to the field of oral pharmaceutical compositions and their use for providing contraception. More specifically, the present invention relates to oral chewable tablets of drospirenone, their use for providing contraception to an individual and a kit comprising daily dosage units of such oral chewable tablets.
The present invention is related to a pharmaceutical composition for nebulization administration comprising an inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA), and optionally a long-acting muscarinic antagonist (LAMA) to be used in the treatment of respiratory diseases, especially in asthma and chronic obstructive pulmonary disease (COPD), and process for the preparation 5 thereof. More particularly, the pharmaceutical compositions herein include beclometasone dipropionate (BPD), formoterol fumarate (FF) and optionally glycopyrronium bromide (GB). The invention also relates to the use of said pharmaceutical formulation in a soft mist inhaler.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
The present invention provides a non-swallowed, antacid chewing gum tablet comprising various antacid components with improved organoleptic properties. The invention also provides an extrusion process for obtaining the non-swallowed, antacid chewing gum tablet as well as the use of the extruded chewing gum tablet as an antacid medicament, and for the prevention and/or the treatment of antacid diseases.
A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
34.
A NON-SWALLOWED, ANTACID CHEWING GUM PRODUCT, A PROCESS FOR ITS PREPARATION AND USES THEREOF
The present invention provides a non-swallowed, antacid chewing gum tablet comprising various antacid components with improved organoleptic properties. The invention also provides an extrusion process for obtaining the non-swallowed, antacid chewing gum tablet as well as the use of the extruded chewing gum tablet as an antacid medicament, and for the prevention and/or the treatment of antacid diseases.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
35.
ORAL PHARMACEUTICAL COMPOSITIONS OF PROGESTERONE AND ESTRADIOL
Novel oral and stable pharmaceutical compositions comprising progesterone or a pharmaceutically acceptable salt thereof in combination with estradiol or a pharmaceutically acceptable salt thereof are provided. The present invention provides novel self-emulsifying systems for pharmaceutical compositions comprising progesterone or pharmaceutically acceptable salt thereof in combination with estradiol, or pharmaceutically acceptable salt thereof which provides good solubility of the two APIs, and/or reduces their bio-degradation. The invention also refers to a process for preparing said pharmaceutical compositions and to the use of said pharmaceutical compositions.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61P 15/12 - Drugs for genital or sexual disordersContraceptives for climacteric disorders
36.
METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTION
The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea, comprising administering drospirenone in a biphasic regimen. The present invention furthermore relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to a pharmaceutical composition and a kit comprising drospirenone administered in such a biphasic regimen.
The present invention concerns a treatment of polycystic ovary syndrome (PCOS) by using specialized pro-resolving lipid mediators (SPM) or their active precursors, optionally in combination with a non-steroidal anti-inflammatory drug.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention relates to a new modified release oral pharmaceutical form comprising 17a- cyanomethyl-17-ß-hydroxyestra-4,9-dien-3-one (dienogest) and 17aa-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
The invention relates to a new modified release oral pharmaceutical form comprising 17α- cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest) and 17aα-ethinylestradiol (ethynyl estradiol), its method of production and its medical and non-medical uses, in particular its use in contraception.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
The present invention is related to a pharmaceutical composition for nebulization administration comprising an inhaled corticosteroid (ICS), a long-acting ?2-agonist (LABA), and optionally a long- acting muscarinic antagonist (LAMA) to be used in the treatment of respiratory diseases, especially in asthma and chronic obstructive pulmonary disease (COPD), and process for the preparation 5 thereof. More particularly, the pharmaceutical compositions herein include beclometasone dipropionate (BPD), formoterol fumarate (FF) and optionally glycopyrronium bromide (GB). The invention also relates to the use of said pharmaceutical formulation in a soft mist inhaler.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The present invention is related to a pharmaceutical composition for nebulization administration comprising an inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA), and optionally a long- acting muscarinic antagonist (LAMA) to be used in the treatment of respiratory diseases, especially in asthma and chronic obstructive pulmonary disease (COPD), and process for the preparation 5 thereof. More particularly, the pharmaceutical compositions herein include beclometasone dipropionate (BPD), formoterol fumarate (FF) and optionally glycopyrronium bromide (GB). The invention also relates to the use of said pharmaceutical formulation in a soft mist inhaler.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
The present invention discloses an oral solid unit dosage form comprising an amount of 3 to 25 mg ivermectin in at least one pharmaceutically acceptable excipient, and a method of treating subjects by administering an oral solid unit dosage form comprising an amount of 3 to 25 mg ivermectin in at least one pharmaceutically acceptable carrier.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The invention relates to vaginal composition comprising a combination of estrogen and vitamin D or a vitamin D analog at a daily dosage delivery of (i) estrogen ranging from 1 μg to 100 μg estrogen of estradiol equivalent and (ii) vitamin D or analog ranging from 7.5 μg to 100 μg of vitamin D equivalent.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
The present invention provides novel softgel capsules of a women health care hormone, as well as to a process for the preparation thereof. In particular, the present invention relates to novel softgel capsules of a women health care hormone, which are capable of reducing allergic reactions, while maintaining an adequate solubility of the hormone in the administration thereof.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
The present invention relates to a process for the preparation of the compound N-(3,5-dimethylphenyl)-N′-(2-trifluoromethylphenyl) guanidine of formula (I) which comprises reacting a salt of a compound of formula (II) or a mixture of the salt of the compound of formula (II) and a compound of formula (II) with a compound of formula (III), in the presence of a polar organic solvent; a crystalline solid form of the compound of formula (I), in particular crystalline solid form A; to a pharmaceutical composition comprising them; and to their use as a medicament, in particular to the treatment of a condition mediated by Rho-GTPase cell proteins.
C07C 277/08 - Preparation of guanidine or its derivatives, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
C07C 277/02 - Preparation of guanidine or its derivatives, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups of guanidine from cyanamide, calcium cyanamide or dicyandiamides
C07C 279/18 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
C07C 277/06 - Purification or separation of guanidine
63.
VAGINAL COMPOSITION COMPRISING A COMBINATION OF ESTROGEN AND VITAMIN D
The invention relates to vaginal composition comprising a combination of estrogen and vitamin D or a vitamin D analog at a daily dosage delivery of (i) estrogen ranging from 1 μg to 100 μg estrogen of estradiol equivalent and (ii) vitamin D or analog ranging from 7.5 μg to 100 μg of vitamin D equivalent.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
64.
A PROCESS FOR THE PREPARATION OF THE COMPOUND N-(3,5-DIMETHYLPHENYL)-N'-(2-TRIFLUOROMETHYLPHENYL) GUANIDINE
The present invention relates to a process for the preparation of the compound N-(3,5-dimethylphenyl)-N'-(2-trifluoromethylphenyl) guanidine of formula (I) which comprises reacting a salt of a compound of formula (II) or a mixture of the salt of the compound of formula (II) and a compound of formula (II) with a compound of formula (III), in the presence of a polar organic solvent; a crystalline solid form of the compound of formula (I), in particular crystalline solid form A; to a pharmaceutical composition comprising them; and to their use as a medicament, in particular to the treatment of a condition mediated by Rho-GTPase cell proteins.
C07C 277/02 - Preparation of guanidine or its derivatives, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups of guanidine from cyanamide, calcium cyanamide or dicyandiamides
C07C 277/06 - Purification or separation of guanidine
C07C 279/18 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
The present invention relates to a process for the preparation of the compound N-(3,5-dimethylphenyl)-N'-(2-trifluoromethylphenyl) guanidine of formula (I) which comprises reacting a salt of a compound of formula (II) or a mixture of the salt of the compound of formula (II) and a compound of formula (II) with a compound of formula (III), in the presence of a polar organic solvent; a crystalline solid form of the compound of formula (I), in particular crystalline solid form A; to a pharmaceutical composition comprising them; and to their use as a medicament, in particular to the treatment of a condition mediated by Rho-GTPase cell proteins.
C07C 277/02 - Preparation of guanidine or its derivatives, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups of guanidine from cyanamide, calcium cyanamide or dicyandiamides
C07C 277/06 - Purification or separation of guanidine
C07C 279/18 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
66.
1,4-cyclohexylamine derivatives and processes for the preparation thereof
The invention relates to a process for the synthesis of Cariprazine, an antipsychotic compound useful in the treatment of positive and negative symptoms associated to schizophrenia, with the following structural formula: (A) The invention further relates to the synthesis of intermediates useful in the preparation of Cariprazine.
C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07C 275/26 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
C07D 233/61 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
C07D 295/033 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
It relates to a device comprising (a) a core comprising polyurethane; (b) a sheath comprising ethylene vinyl acetate copolymer, said sheath substantially or completely surrounding said core; and (c) one or more active pharmaceutical ingredients dissolved or dispersed in said core and/or said sheath; and to a process for its preparation.
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/00 - Medicinal preparations characterised by special physical form
A61F 6/14 - Contraceptive devicesPessariesApplicators therefor for use by females intra-uterine type
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and veterinary products; vitamins,
nutritional supplements, mineral food supplements, dietary
supplements for medical use, dietetic and nutritional
supplements, dietetic foodstuffs for dieting and medicinal
preparations for slimming. Medical, surgical, dental or veterinary apparatus and
instruments; artificial limbs, eyes and teeth; orthopedic
articles; suture materials, parts of all the aforesaid
goods.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparation for use in treating digestive diseases and disorder, gynecological diseases and disorders, blood disorders, cancer, cardiovascular diseases, vascular diseases, gastrointestinal diseases, genitourinary diseases, respiratory system diseases, circulatory system diseases, glaucoma, dental and oral diseases, headaches, migraine, obesity, hepatic diseases, cholesterol, blood pressure and rheumatic treatments; veterinary preparation for treating digestive diseases and disorder, gynecological diseases and disorders, blood disorders, cancer, cardiovascular diseases, vascular diseases, gastrointestinal diseases, genitourinary diseases, respiratory system diseases, circulatory system diseases, glaucoma, dental and oral diseases, headaches, migraine, obesity, hepatic diseases, cholesterol, blood pressure and rheumatic treatments; dietetic foods adapted for medical use for maintaining and improving general health and well-being; vitamins
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Bleaching preparations and other substances for laundry use; Cleaning, polishing, scouring and abrasive preparations; Soaps; Dentifrices; Perfumery; Essential oils; Cosmetics; Hair lotion. Contraceptive pharmaceutical preparations, including periodic oral contraceptives, chemical contraceptives and contraceptive preparations; Veterinary preparations; Dietetic food and substances adapted veterinary use, food for babies; Dietary supplements for animals; Plasters, materials for dressings; Disinfectants; Preparations for destroying vermin; Fungicides; Herbicides; None of the aforesaid goods relating to the field of dentistry, dental technique and the treatment of diabetes. Surgical apparatus and instruments related to contraception; contraceptive medical devices.
The invention relates to a process for the synthesis of Cariprazine, an antipsychotic compound useful in the treatment of positive and negative symptoms associated to schizophrenia, with the following structural formula: (A) The invention further relates to the synthesis of intermediates useful in the preparation of Cariprazine.
C07D 233/61 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
C07C 275/26 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
C07D 295/033 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
75.
INHALABLE PARTICLES COMPRISING TIOTROPIUM AND INDACATEROL
The present invention relates to inhalable particles comprising an intimate mixture which consists of a) an amorphous tiotropium compound, b) an amorphous indacaterol compound, and c) a sugar derivative, wherein the weight of the sugar derivative is comprised from 0 to 85% relative to the weight of the inhalable particles. It also relates to a pharmaceutical composition comprising the inhalable particles of the invention, to a process for their preparation, and to their use in the treatment of asthma or chronic obstructive pulmonary disease (COPD).
There is described an oxygen-selective alkylation reaction of an amino alcohol of general formula (I) with a compound of general formula (IV) to produce an O-alkylated compound of general formula (II), avoiding the need to protect the amino group of the starting compound, according to the scheme. There is also described a process for the preparation of allosteric antagonists of ADP receptors, in particular Ticagrelor, or of intermediates useful for their preparation, which uses the oxygen-selective alkylation reaction.
The present invention relates to a dosage form which comprises amorphous calcium L-5-methylfolate and cysteine as stabilizing agent and optionally, further auxiliary agents. The dosage forms according to the invention resolves the problem of instability of amorphous calcium L-5- methylfolate to the oxidation by air.
Provided herein are phenyl-guanidine derivatives for the inhibition of Rac1 which blocks its interaction with guanosine exchange factors (GEFs) belonging to the DBL family as agents for the treatment of aggressive and/or resistant tumors, as well as pharmaceutical compositions comprising them, their use in therapy and processes for their preparation.
C07C 277/08 - Preparation of guanidine or its derivatives, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
C07C 279/18 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 235/30 - Nitrogen atoms not forming part of a nitro radical
C07D 263/48 - Nitrogen atoms not forming part of a nitro radical
C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
C07D 277/48 - Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary products; vitamins,
nutritional supplements, mineral food supplements, dietary
supplements for medical use, dietetic and nutritional
supplements, dietetic foodstuffs for dieting and medicinal
preparations for slimming.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary products; vitamins,
nutritional supplements, mineral food supplements, dietary
supplements for medical use, dietetic and nutritional
supplements, dietetic foodstuffs for dieting and medicinal
preparations for slimming.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, veterinary and dietetic preparations adapted for medical use, excluding food supplements for the pre-conception period, for the pregnancy and for the nursing.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, veterinary and dietetic preparations for medical purposes, not consisting of RNA (ribonucleic acid) molecules involved in gene silencing.
It relates to a device comprising (a) a core comprising polyurethane; (b) a sheath comprising ethylene vinyl acetate copolymer, said sheath substantially or completely surrounding said core; and (c) one or more active pharmaceutical ingredients dissolved or dispersed in said core and/or said sheath; and to a process for its preparation.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/00 - Medicinal preparations containing organic active ingredients
It relates to a device comprising (a) a core comprising polyurethane; (b) a sheath comprising ethylene vinyl acetate copolymer, said sheath substantially or completely surrounding said core; and (c) one or more active pharmaceutical ingredients dissolved or dispersed in said core and/or said sheath; and to a process for its preparation.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61F 6/14 - Contraceptive devicesPessariesApplicators therefor for use by females intra-uterine type
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided herein are phenyl-guanidine derivatives for the inhibition of Rac 1 which blocks its interaction with guanosine exchange factors (GEFs) belonging to the DBL family as agents for the treatment of aggressive and/or resistant tumours, as well as pharmaceutical compositions comprising them, their use in therapy and processes for their preparation.
C07C 279/18 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
Provided herein are phenyl-guanidine derivatives for the inhibition of Rac1 which blocks its interaction with guanosine exchange factors (GEFs) belonging to the DBL family as agents for the treatment of aggressive and/or resistant tumours, as well as pharmaceutical compositions comprising them, their use in therapy and processes for their preparation.
C07C 279/18 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
C07D 233/28 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
